MSNews updates are on hold until further notice. Sign-up on our mailing list here to be notified when we are back.
August 28, 2008
Submitted by art on Fri, 2008-08-29 06:35.
ATL1102 is a drug, similar to Tysabri, developed by Antisense Therapeutics.
On 30 June 2008 Teva and Antisense Therapeutics announced the results of the Phase IIa MS trial and reported that ATL/TV1102 (ne ATL1102) significantly reduced disease activity in patients with RRMS and that the Phase IIa study met its primary endpoint showing a significant reduction by 54.4% in cumulative number of new active lesions in patients taking ATL/TV1102 for 8 weeks, compared to placebo, as measured by magnetic resonance images (MRI). ATL/TV1102 demonstrated an increasing effect with time on the reduction of new active lesions over 12 weeks - one month after the completion of dosing.
Submitted by art on Fri, 2008-08-29 06:34.
IPX056 has met its clinical endpoints in Impax Laboratories’ Phase III study of spasticity in multiple sclerosis patients.
The drug is an extended-release formulation of baclofen, a common treatment for spasticity, which has the potential to offer improved control of symptoms and dosing convenience, according to Impax.